Abbott (ABT) Begins Post-Approval Study of XIENCE V(TM) Drug Eluting Stent
More News related to ABT
- Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania
- AngioScore Submits Citizen Petition Requesting FDA Action to Deny Patent Term Extension Based on Abbott Angioplasty Catheter
- Abbott Labs (ABT) to Streamline Operations; Sees $370 Million in Pre-Tax Charges
- Patient Side Point-of-Care Testing in the Emergency Department Enables Quicker Treatment Decisions for Patients With Chest Pain
- Absolute's Computrace LoJack for Laptops Now Available at Future Shop
More News related to Corporate News
- Sapient (SAPE) Announces Completion of Stock Option Investigation
- NuStar Pipeline (NS) Expansion to Increase Fuel Supply to Northern Midwest States
- Westaff (WSTF) Signs Second Forbearance Agreement
- Allegheny Power (AYE) Files for Rate Increase in West Virginia
- JAKKS Pacific (JAKK) Announces Dismissal of Court Action Against World Wrestling Entertainment (WWE)
Abbott (NYSE: ABT) announced the start of the XIENCE V(TM) USA post-approval study, with six hospital centers already recruiting and enrolling patients just one week after the U.S. Food and Drug Administration approved the XIENCE V(TM) Everolimus Eluting Coronary Stent System. The XIENCE V USA study will evaluate the safety and effectiveness of the XIENCE V drug eluting stent in a real-world clinical setting out to five years. Jack Jones, M.D., interventional cardiologist and medical director of the Stormont-Vail Catheterization Lab in Topeka, Kan., was one of the first physicians to enroll a patient into the study.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-1.32Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
